Redressing the interactions between stem cells and immune system in tissue regeneration

Jiankai Fang1†, Chao Feng1,2†, Wangwang Chen3, Pengbo Hou1,2, Zhanhong Liu1,2, Muqiu Zuo1, Yuyi Han1,2, Chenchang Xu1, Gerry Melino2, Alexei Verkhratsky4, Ying Wang5*, Changshun Shao1* and Yufang Shi1,5*

Abstract
Skeletal muscle has an extraordinary regenerative capacity reflecting the rapid activation and effective differentiation of muscle stem cells (MuSCs). In the course of muscle regeneration, MuSCs are reprogrammed by immune cells. In turn, MuSCs confer immune cells anti-inflammatory properties to resolve inflammation and facilitate tissue repair. Indeed, MuSCs can exert therapeutic effects on various degenerative and inflammatory disorders based on their immunoregulatory ability, including effects primed by interferon-γ (IFN-γ) and tumor necrosis factor-α (TNF-α). At the molecular level, the tryptophan metabolites, kynurenine or kynurenic acid, produced by indoleamine 2,3-dioxygenase (IDO), augment the expression of TNF-stimulated gene 6 (TSG6) through the activation of the aryl hydrocarbon receptor (AHR). In addition, insulin growth factor 2 (IGF2) produced by MuSCs can endow maturing macrophages oxidative phosphorylation (OXPHOS)-dependent anti-inflammatory functions. Herein, we summarize the current understanding of the immunomodulatory characteristics of MuSCs and the issues related to their potential applications in pathological conditions, including COVID-19.

Keywords: MuSCs, Immune cells, Immunomodulation, Muscle repair, Tissue regeneration

Introduction
For centuries, biologists have been puzzled with the near perfect ability to regenerate severed body parts in certain animals. Planarians, for example, even after being sliced into 100 segments, demonstrate remarkable regeneration when each of the pieces develops into individual worm with normal adult structure. A salamander completely regrows amputated limbs with normal tissue structures and functions [1–4]. Mechanisms of accurate coordination of diverse and complex biological processes, including, but not limited to, angiogenesis, skeletal reconstruction, muscle layout, and nerve innervation during tissue regeneration remain largely elusive and merit further investigations.

Tissue regeneration is a highly orchestrated process that is often accompanied by inflammation. The infiltration of immune cells into the injured site is one of the earliest detectable responses to tissue damage. Various aspects of inflammation, such as the duration, severity, and the types of immune response, determine the outcomes of tissue regeneration [5–7]. Persistent deregulated inflammation at the injury site derails the regeneration process and eventually leads to the formation of tissue fibrosis and scars. Successful tissue regeneration requires an orderly coordination of activation and waning of different types of inflammatory responses.
mediated by distinct immune cell populations [8]. The immune aspect of tissue repair was not appreciated until Elie Metchnikoff discovered the role of macrophages in starfish wound healing in 1882 when being in Messina [9]. Numerous breakthroughs have been made over the recent two decades and laid a solid foundation for understanding the pathogenesis of traumatic diseases and for developing more efficient therapies, including the effects on redox, epigenetics, transcriptional, degradative, apoptotic and autophagic mechanisms [10–26].

Skeletal muscle is a major immunomodulatory organ [27]. In addition to myogenic cells, a large number of immune cells reside in healthy skeletal muscle tissue. There are 500 to 2000 leukocytes per mm³ of adult rodent limb muscles. Skeletal muscle is the largest tissue, accounting for approximately 35% of the total body mass of a human and containing about 10⁹ leukocytes per liter of muscle tissue. Total number of leukocytes in a typical adult is 4 × 10¹⁰, while there are 4 × 10¹⁰ leukocytes in the entire muscle [28]. T cells, neutrophils and eosinophils are less abundant in healthy skeletal muscle, whereas monocytes and macrophages account for the majority of resident immune cell populations. They are scattered in the interstices of muscle connective tissue and around blood vessels [29, 30]. The muscle immune system represents an excellent platform for investigating the interactions between stem cells and immune cells in tissue regeneration.

Muscle damage caused by trauma, burns, freezing, toxins, over-exercise or certain diseases often disrupts the original tissue structure. Muscle stem cells (MuSCs; satellite cells), laying along the fully differentiated myofibers, exit quiescence state and execute the stereotypical myogenesis program in response to muscle damage. The process of recruiting MuSCs into the reparative action can be broadly divided into (i) an early stage of MuSC activation and proliferation, and (ii) a later stage of terminal differentiation and growth [28, 31]. This regenerative process is accompanied by two distinct immunological phases: (i) the pro-inflammatory phase, where leukocytes migrate towards the injured site to exert pro-inflammatory functions and govern MuSC activation and proliferation, and (ii) the anti-inflammatory or restorative phase, which is characterized by myogenic lineage differentiation, growth of new myofibers, angiogenesis, and extracellular matrix (ECM) deposition and remodeling [32, 33] (Fig. 1).

Regulation of myogenesis by pro-inflammatory responses

Immune cells are temporally and spatially orchestrated in response to muscle injury. Complement system, the first sensor of muscle damage, is rapidly activated in the injured area [34]. Subsequently, a cellular response occurs, during which activated resident mast cells swiftly degranulate and release pro-inflammatory cytokines to recruit other immune cells to muscle lesions [35, 36]. Within hours, neutrophils, among the first wave of peripheral immune cells, extravasate from circulation and enter the injured area, clean necrotic debris, and mount a pro-inflammatory response [37]. Waves of pro-inflammatory cytokines, such as IFN-γ, IL-1β, TNF-α, IL-1 and IL-8, are secreted from neutrophils and induce the infiltration of circulating monocytes to establish the early inflammatory microenvironment and the subsequent degradation of injured tissues [38, 39]. Macrophages, the professional phagocytes of the immune system, scavenge cellular debris to prevent the persistence of potentially toxic or immunogenic materials in the muscle environment [8, 40]. The fibro/adipocyte progenitors (FAPs), activated by IL-4 derived from eosinophils, are the non-professional phagocytes that mediate rapid debris clearance [41]. Surprisingly, compared to macrophages, FAPs were four-fold more efficient at phagocytizing necrotic thymocytes obtained through iterative cycles of freeze/thaw in liquid nitrogen in vitro [41].

The muscle environment orchestrated by macrophages and enriched with pro-inflammatory cytokines is essential for the initial stages of myogenesis. The destruction of CCL2/CCR2 axis, the main attractant of circulating monocytes into a damaged site, through genetic ablation of Ccl2 or its receptor Ccr2 reduced infiltrating macrophage numbers in injured muscle, and was accompanied by slowed growth of nascent muscle fibers [42–45]. Other parallel investigations employing myeloid depletion models (clodronate, CD11b-DTR mouse) also highlighted the absolute requirement of macrophages in governing muscle inflammation and triggering myogenic program following injury [46]. In addition, complement protein C3a has been implicated in promoting the trafficking of macrophages in damaged muscles to facilitate tissue regeneration [47].

However, infiltrating macrophages exhibit distinct phenotypic characteristics and functions in different phases of skeletal muscle regeneration [32, 48]. The dichotomy between M1 (classically activated) and M2 (alternatively activated) macrophages represents distinct polarized phenotypes, signifying the transition from a pro-inflammatory to an anti-inflammatory/restorative profile. Nevertheless, this M1-M2 terminology does not reflect sequential and pleiotropic characteristics of infiltrating macrophages [49]. Ly6C⁺ or MHC⁺ macrophages that first arrive at the injury site and the Ly6C⁻ or MHC⁺ macrophages present in the later phases of skeletal muscle regeneration may represent M1-biased and M2-biased populations, respectively [50,
M1 macrophages contribute to a spectrum of pro-inflammatory cytokines, including, but not limited to, IFN-γ, TNF-α, IL-1β and IL-6, conditioning the immune microenvironment to promote the rapid proliferation of MuSCs and simultaneously restrain the early differentiation steps of MuSCs [48, 52–56]. Moreover, these pro-inflammatory macrophages, through their expression of TNF-α, directly induce apoptosis of FAPs, thus regulating their number and ultimately preventing pathological muscle fibrosis [57]. Macrophage-derived niche signals are vital for MuSC proliferation. The ‘dwelling’ macrophages, a specific subset of macrophages within the injury area, secrete nicotinamide phosphoribosyl-transferase (NAMPT), which, as mitogenic stimuli, activates MuSCs through CCR5 [58]. However, the variety and concentration of inflammatory factors produced by myeloid cells cannot meet the needs of extensive expansion of MuSCs. Hence, T cells play an important role in conditioning the endogenous inflammatory microenvironment and maintaining exponential growth of MuSCs. Specifically, the cocktail of four cytokines (IL-1α, IL-13, IFN-γ and TNF-α) secreted from activated T cells assures MuSC expansion in Rag1−/− mice that lack T cells but have intact macrophages, and promoted the proliferation of undifferentiated MuSCs through 20 passages in vitro [59]. The addition of these four cytokines in culture medium, mimicking the endogenous inflammatory microenvironment, presents a promising method to efficiently expand MuSCs without loss of self-renewing potency, and breaks the bottleneck that had limited long-term serial expansion of functional MuSCs to meet the demands for clinical therapeutic applications [60].
Regulation of myogenesis by anti-inflammatory responses
The resolution of inflammation, associated with the transition from the pro-inflammatory to the anti-inflammatory phase, is functionally coupled to the transition of regeneration states from the proliferative stage to the differentiation and growth stage of myogenesis and is required for tissue recovery [28]. M2 macrophages are crucial in avoiding detrimental inflammation and returning to tissue homeostasis. They contribute to myogenesis, angiogenesis, and ECM remodeling through reciprocal interactions with surrounding cells, including MuSCs, endothelial cells and FAPs [48, 50, 57, 61, 62]. Advances have recently been made in the understanding of the mechanisms governing the spatiotemporal phenotype shift of macrophages. Various metabolic programs can control macrophage inflammatory status [63, 64]. Mass spectrometry-based lipidomics coupled with transcriptomics identified a temporal shift of lipid metabolism, from pro-inflammatory lipid mediators (e.g., leukotrienes, prostaglandins) to specialized pro-resolving lipid mediators (e.g., resolvin and lipoxins), in the transition from Ly6C⁺ macrophages to Ly6C⁻ macrophages [65]. In particular, activation of the metabolic regulator AMP-activated protein kinase α1 (AMPKα1) is required for the shift of macrophage polarization. Myeloid-specific deletion of AMPKα1 using lysozyme M-Cre (LysM-Cre) mouse strain resulted in exacerbated muscle damage [57], deletion of AMPKα1 using lysozyme M-Cre (LysM-Cre) the shift of macrophage polarization. Myeloid-specific activated protein kinase α1 (AMPKα1) is required for the shift of macrophage polarization. Myeloid-specific deletion of AMPKα1 using lysozyme M-Cre (LysM-Cre) mouse strain resulted in exacerbated muscle damage.

Mechanisms of immunomodulation by MuSCs
Muscle regeneration involves highly coordinated cellular responses between different varieties of immune cells and MuSCs. Disturbance of the coordination between the different types of cells will lead to delay or even failure of muscle repair. The synchronized functional changes of trafficking macrophages during skeletal muscle regeneration directly determine MuSC fate and myogenesis progress. Inflammatory factors released from activated T cells in high concentrations promote MuSCs to enter the cell cycle and rapidly proliferate, thus ensuring plenty of stem cell reserves for muscle regeneration. Mounting evidence has confirmed the critical roles of immune cells in directing the fate of MuSCs. However, it is unclear whether there is a bidirectional interaction between immune cells and MuSCs so that MuSCs can in turn regulate the functions of immune cells.

Skeletal muscle is not only an important endocrine tissue, but also one of the main immunomodulatory organs [27]. Myocytes, non-professional antigen-presenting cells, actively participate in the functional regulation of immune cells under physiological and pathological conditions. Myocytes participate in the innate immune response and affect adaptive immunity through secreting myokines [77]. Muscle trauma is accompanied by prominent myocyte necroptosis, in which tenascin-C released by necroptotic myofibers promotes MuSC proliferation to facilitate muscle regeneration [78]. Beside myocytes, do MuSCs, the main myogenic cells in the damaged tissue microenvironment endowed mitogenic functions of necroptosis and pro-inflammatory cytokines, also possess immunomodulatory properties?

We have recently addressed this question experimentally using an inflammatory bowel disease (IBD) model in vivo (Fig. 2). We identified a novel anti-inflammatory function of MuSCs that is based on their production of IGF2. By endowing maturing macrophages an oxidative phosphorylation (OXPHOS)-dependent anti-inflammatory property, the IGF2-producing MuSCs can thus orchestrate an anti-inflammatory microenvironment that favors tissue repair and regeneration in colon tissues [79]. TNF-stimulated gene 6 (TSG6), an important immunoregulatory factor, can suppress inflammation by inducing pro-inflammatory macrophages to adopt an anti-inflammatory phenotype in colon tissue microenvironment endowed mitogenic functions of necroptosis and pro-inflammatory cytokines, also possess immunomodulatory properties?

We have recently addressed this question experimentally using an inflammatory bowel disease (IBD) model in vivo (Fig. 2). We identified a novel anti-inflammatory function of MuSCs that is based on their production of IGF2. By endowing maturing macrophages an oxidative phosphorylation (OXPHOS)-dependent anti-inflammatory property, the IGF2-producing MuSCs can thus orchestrate an anti-inflammatory microenvironment that favors tissue repair and regeneration in colon tissues [79]. TNF-stimulated gene 6 (TSG6), an important immunoregulatory factor, can suppress inflammation by inducing pro-inflammatory macrophages to adopt an anti-inflammatory phenotype in LPS-induced acute lung injury and dextran sulfate sodium (DSS)-induced colitis model [80, 81]. MuSCs stimulated by inflammatory factors IFN-γ and TNF-α exhibit an anti-inflammatory function that depends on the indoleamine 2,3-dioxygenase (IDO)-TSG6 axis in IBD mice. Mechanistically, the
IDO metabolites kynurenine (KYN) or kynurenic acid (KYNA) promote TSG6 expression through activating aryl hydrocarbon receptor (AHR) signaling [82]. Thus, MuSCs do not only respond to inflammatory cues in damage microenvironment but also act on immune cells to shape immune microenvironment to facilitate tissue repair. The new discovery of MuSCs-based immunomodulatory ability expands the potential applications of stem cell therapies in pathological conditions beyond muscle-related diseases.

**New modes of MuSC-based therapy**

There has been a long-standing debate about stem cell-based regeneration and repair mechanism, is it based on cell replacement or cell empowerment. Indeed, only few transplanted stem cells are capable of differentiating into daughter cells at the damaged site or even persisting for a sufficiently long period in vivo [83]. In addition, the results from animal experiments of xenotransplantation and preclinical studies of allogeneic stem cell transplantation have clearly demonstrated therapeutic potentials of stem cell ‘decellularization,’ thus strongly supporting cell empowerment as the paradigm of stem cell therapy. Stem cells ‘licensed’ by inflammatory factors can dictate the phenotypes and functional metamorphoses of immune cells by producing immunoregulatory factors, and guide the outcomes of inflammation in various diseases. Mesenchymal stem cells (MSCs) can unleash powerful therapeutic effects under different kinds of inflammatory conditions via cell empowerment [84, 85]. In our study, we found that the MuSC secretome possessed a therapeutic efficacy equivalent to that of MSCs in IBD mice, thus indicating that MuSCs can promote tissue repair indirectly through cell empowerment [79]. It was also demonstrated that MuSCs’ exosomes could prevent excessive ECM deposition and facilitate muscle regeneration via regulating collagen expression in fibrogenic cells [86]. Further validation of cell empowerment
or promotion of tissue homeostasis by stem cells in physiological and pathological conditions will advance our understanding of MuSC biology and expand the application scope of MuSCs.

IGF2, a strong mitogen for MuSCs [87], is a vital immunomodulatory mediator that confers maturing macrophages anti-inflammatory properties [79, 88, 89]. The actions of IGF2 are coupled temporally and spatially to the myogenesis program between MuSC proliferation and immunomodulation. During the early stage of muscle regeneration, MuSCs produce IGF2 to promote self-proliferation and expansion. However, along with the mounting number of MuSC populations, the local concentration of IGF2 in tissue microenvironments becomes sufficiently high to determine the inflammatory phenotypes of infiltrating immune cells. In this scenario, the tissue microenvironment completes the transition from a pro-inflammatory to an anti-inflammatory phase with the assistance of MuSCs. The resolution of inflammation is required for tissue recovery, in which MuSCs stop proliferation and enter the differentiation process. Therefore, in the early stage of muscle regeneration, IGF2 acts as a ‘throttle’ of MuSC proliferation response, while in the late stage of muscle regeneration, abundant IGF2 functions as the ‘brake’ of MuSC proliferation response through inducing resolution of inflammation (Fig. 1). The distinct actions of IGF2 in different phases ensure that those controllable MuSC populations can be fully applied to the subsequent muscle differentiation process, avoiding excessive accumulation of activated MuSCs in local tissue, and improving the application of stem cell during tissue regeneration.

The immunomodulatory ability of MuSCs represents a new mechanism of action by stem cells in the treatment of muscle-related diseases. Immunological and inflammatory processes downstream of dystrophin deficiency contribute to muscle pathology in duchenne muscular dystrophy (DMD). Modulating the inflammatory response and inducing immunological tolerance to de novo dystrophin expression are critical to the success of dystrophin-replacement therapies [90]. The transplantation of MuSCs from healthy donors to DMD patients is based on the assumption that nascent muscle will be formed from the transplanted stem cells. Our findings suggest that MuSCs may also function in taming inflammation in damaged muscle. MuSC-mediated immunomodulation could be of continued importance in completing normal differentiation program and achieving successful dystrophin-replacement therapy. In addition, the immunomodulatory ability of MuSCs provides new potential venues in the treatment of inflammatory diseases by MuSCs. MuSC secretome as a new therapeutic agent can greatly reduce allograft rejection reaction of treated patients, while reducing safety and ethical risks, and facilitate therapeutic effects of stem cells in various inflammatory diseases.

A novel therapeutic use in the COVID-19 pandemic
The pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused over 4 million deaths up to the present. SARS-CoV-2 infection results in a broad spectrum of clinical manifestations, including both reproductive and neurological implications [91–94]. Indeed, COVID-19 is characterized by excessive production of pro-inflammatory cytokines and acute lung damage associated with patient mortality [95–100]. Various clinical trials based on the potent immunoregulatory ability of MSCs were launched in different countries in various cases with COVID-19 infection. MSC administration appeared to be efficacious in ameliorating over-activated inflammation, contributing to recovery from lung damage, preventing long-term pulmonary disability, and reducing mortality. In addition, MSC infusion in COVID-19 patients had excellent safety [101–108] (Table 1). In this scenario, the therapeutic efficacy of MuSCs equivalent to that of MSCs can be applied in the suppression of hyperactive immune response and promotion of tissue repair, as in DSS-induced IBD.

Perspective
As mentioned above, MuSCs do not only have well-known muscle differentiation functions, but also possess important immunomodulatory properties. The relationship between MuSCs and immune cells is bidirectional. In addition to passively receiving inflammatory cues from immune cells for proliferation and differentiation, MuSCs can also actively secrete immunomodulatory factors to induce the resolution of inflammation. Based on the immunoregulatory effect of stem cells, more than 1000 clinical disease treatment studies of MSCs have been carried out around the world. However, there are only dozens of cases of clinical research involving MuSCs, and they are fully focused on the treatment of skeletal muscle diseases based on the muscle differentiation function of MuSCs. The research on the immunoregulatory function of MuSCs will further broaden the application fields of MuSCs. MuSCs are expected to become one of the important stem cell types for the treatment of inflammatory diseases in the foreseeable future.

Authors’ contributions
GM, AV, YW, CS and YS conceived the project; JF and CF wrote the manuscript; WC, PH, ZL, MZ, YH and CX contributed to literature collection and discussion; JF and CF prepared Figs. 1 and 2 through BioRender.com. All authors read and approved the final manuscript.
### Table 1: Clinical studies of MSC treatment for COVID-19 patients

| Trial ID        | Trial design                        | Indications          | MSC source                  | Dose and routes of MSC administration | Number of patients | Clinical outcomes                                                                 | Refs |
|-----------------|-------------------------------------|----------------------|-----------------------------|----------------------------------------|--------------------|-----------------------------------------------------------------------------------|------|
| ChiCTR2000029990 | Phase 1, open-label, single-center, case–control | Moderate/Severe/Critical | Clinical grade MSCs | $1 \times 10^6$ cells/kg, i.v. | 10 | The pulmonary functions and symptoms were significantly improved after MSC infusion. | 101  |
| ChiCTR2000031494 | Phase 1, open-label, randomized, standard treatment–control | Severe/Critical | Umbilical cord | $2 \times 10^6$ cells/kg, i.v | 41 | MSC infusion showed improved clinical manifestations. | 102  |
| NCT04252118     | Phase 1, open-label, single-center, case–control | Moderate/Severe | Umbilical cord | $3 \times 10^7$ cells/dose, i.v | 18 | Intravenous MSC infusion in moderate and severe COVID-19 patients was safe and well-tolerated. | 103  |
| NCT04269525     | Phase 2, case–control                | Severe/Critical | Umbilical cord | $1 \times 10^7$ cells/dose, i.v | 16 | MSC infusion showed improvement in ventilatory, radiological and biological parameters. No MSC infusion related adverse or allergic reactions and no delayed hypersensitivity or secondary infections were reported. | 104  |
| NCT04288102     | Phase 2, randomized, double-blind, placebo-control | Severe | Umbilical cord | $4 \times 10^7$ cells/dose, i.v | 100 | MSC infusion was safe and exerted improvement in total lung lesion proportion and solid component lesion. There was an increased 6-min walking distance in MSC group. | 105  |
| NCT04348461     | Phase 1, prospective nonrandomized open-label cohort | Severe/Critical | Adipose tissue | $1 \times 10^6$ cells/kg, i.v | 13 | No MSC infusion-associated adverse events were reported. Improvement in ventilatory, radiological and biological parameters was associated with clinical status. | 106  |
| NCT04355728     | Phase 1/2a, randomized, double-blind | ARDS                  | Umbilical cord | $10 \pm 2 \times 10^7$ cells/dose, i.v | 24 | MSC infusion was safe. The levels of pro-inflammatory cytokines were significantly decreased, and patient survival and recovery time were improved. | 107  |
| IRCT20200217046526N2 | Phase 1                           | ARDS                  | Umbilical cord and placental | $2 \times 10^6$ cells/dose, i.v | 11 | MSC infusion in critical illness COVID-19 patients was safe and well-tolerated. MSC group had improved respiratory distress and reduced inflammatory signatures. | 108  |

MSC, mesenchymal stem cell; i.v., intravenous injection; ARDS, acute respiratory distress syndrome.
Funding
This study was supported by funds from the Scientific Innovation Project of the Chinese Academy of Sciences (XDA16020403), the National Key R&D Program of China (2018YFA0107500), the National Natural Science Foundation of China (81903085, 81672797, 81530043, and 81802864), State Key Laboratory of Radiation Medicine and Protection, Soochow University (GZN201804 and GZN2101903), National Center for International Research-Cambridge-Su Genomic Research Center (2017B01012), the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (20KJB180005), the AssociazioneItaliana per la Ricerca contro i Cancro (AIRC) (IG20473; 2018-2022), Fondazione Luigi Maria Monti IDI-RICCS (R.C.), Ministry of Health & MAECI Italy-China Science and Technology Cooperation (PPIGR00961) and Regione Lazio through Lazio Innova Progetto Gruppo di Ricerca n 85-2017-14986; n 33 & S5-2021-T0002E0001.

Availability of data and materials
Not applicable.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
GM, AV, YW and YS are members of the Editorial board of Biology Direct. The authors declare that they have no financial or ethical competing interests.

Author details
1 The Third Affiliated Hospital of Soochow University, Institutes for Translational Medicine, State Key Laboratory of Radiation Medicine and Protection, Medical College of Soochow University, 199 Renai Road, Suzhou 215123, Jiangsu, People’s Republic of China. 2 Department of Experimental Medicine and Biochemical Sciences, TOR, University of Rome Tor Vergata, Rome, Italy. 3 Laboratory Animal Center, Medical College of Soochow University, Suzhou, Jiangsu, People’s Republic of China. 4 Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PT, UK. 5 Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, 320 Yuyang Road, Shanghai 200031, People’s Republic of China.

Received: 18 September 2021 Accepted: 12 October 2021
Published online: 20 October 2021

References
1. Haas BJ, Whited JL. Advances in decoding axolotl limb regeneration. Trends Genet. 2017;33(8):553–65.
2. Nacu E, Tanaka EM. Limb regeneration: a new development? Annu Rev Cell Dev Biol. 2011;27:409–40.
3. Reddien PW. The cellular and molecular basis for planarian regeneration. Trends Cell Biol. 2011;21(5):304–11.
4. Aboobaker AA. Planarian stem cells: a simple paradigm for regeneration? Macromol Biosci. 2016;16(6):847–58.
5. Lamatra FR, De Angelis R, Antonucci A, Salvatori D, Procopio P, Casalbony M, Congestri R, Melino S, Nanni F. Polymer composite random lasers based on diatom frustules as scatterers. Rsc Adv. 2014;4(106):61809–16.
6. Ciocci M, Mochi F, Carotenuto F, Di Giovanni E, Procopio P, Francini R, De Matteis F, Reshelev I, Casalbony M, Melino S, et al. Scaffold-in-scaffold potential to induce growth and differentiation of cardiac progenitor cells. Stem Cells Dev. 2017;26(19):1438–47.
7. Aurora AB, Olson EN. Immune modulation of stem cells and regeneration. Cell Stem Cell. 2014;15(1):14–25.
8. Metchnikoff E. Lectures on the comparative pathology of inflammation; delivered at the Pasteur Institute in 1891. New York: Dover; 1968.
9. Pallucca R, Visconti S, Camoni L, Cesareni G, Melino S, Panni S, Torrelli P, Aduccio P. Specificity of epsilon and non-epsilon isoforms of arabidopsis 14-3-3 proteins towards the H4–ATPase and other targets. PLoS One. 2014;9(6):e90764.
10. Lin C, Li H, Liu J, Hu Q, Zhang S, Zhang N, Liu L, Dai Y, Cao D, Li X, et al. Arginine hypomethylated-mediated proteasomal degradation of histone H4–an early biomarker of cellular senescence. Cell Death Differ. 2020;27(9):2697–709.
11. Melino S, Nepravishta R, Bellomaria A, Di Marco S, Paci M. Nuclear acid binding of the RTN1-C-C-terminal region: toward the functional role of a reticulin protein. Biochemistry. 2009;48(2):242–53.
12. Liu Z, Zhang H, Hu Y, Liu D, Li C, Wang Q, Huo J, Liu H, Xie N, et al. Critical role of histone H3 lysine 27 demethylase Kdm6b in the homeostasis and function of medullary thymic epithelial cells. Cell Death Differ. 2020;27(10):2843–55.
13. Lee H, Hong Y, Kong G, Lee DH, Kim M, Tran Q, Cho H, Kim C, Park S, Kim SH, et al. Yin Yang 1 is required for PHD finger protein 20-mediated myogenic differentiation in vitro and in vivo. Cell Death Differ. 2020;27(12):3321–36.
14. Bellomaria A, Barbato G, Melino G, Paci M, Melino S. Recognition of p63 by the E3 ligase ITCH: effect of an ectodermal dysplasia mutant. Cell Cycle. 2010;9(18):3730–9.
15. Perna S, Pinoli P, Ceri S, Wong L. NAUTICA: classifying transcription factor interactions by positional and protein–protein interaction information. Biol Direct. 2020;15(1):13.
16. Mainieri A, Haig D. Retrotransposon gag-like 1 (RTL1) and the molecular evolution of self-targeting imprinted microRNAs. Biol Direct. 2019;14(1):18.
17. Pothy L. Exxon-skipping-rich transcripts of animals reflect the significance of exon–shuffling in metazoan proteome evolution. Biol Direct. 2019;14(1):2.
18. Zhang N, Zhang Y, Qian H, Wu S, Cao L, Sun Y. Selective targeting of ubiquitination and degradation of PARP1 by E3 ubiquitin ligase WW2 regulates isoproterenol–induced cardiac remodeling. Cell Death Differ. 2020;27(9):2625–19.
19. Dampaard RB, Jolin HE, Allison MED, Davies SE, Titheradge HL, Mckenzie ANJ, Komander D. OTULIN protects the liver against cell death, inflammation, fibrosis, and cancer. Cell Death Differ. 2020;27(5):1457–74.
20. Roberts JZ, Holohan C, Sessler T, Fox J, Crawford N, Riley JS, Khawaja H, Majkut J, Evergreen E, Humphreys LM, et al. The SCF(Skp2) ubiquitin ligase complex modulates TRAIL-R2-induced apoptosis by regulating FLIP(L). Cell Death Differ. 2020;27(9):2726–41.
21. Yu H, Ding J, Zhu H, Jing Y, Zhou H, Tian H, Tang K, Wang G, Wang X. LOXL1 confers antiapoptosis and promotes gliomagenesis through stabilizing BAG2. Cell Death Differ. 2020;27(11):3021–36.
22. Stadler KV, Villunger A. Uncovering the PIDDosome and caspase-2 as regulators of organogenesis and cellular differentiation. Cell Death Differ. 2020;27(7):2037–47.
23. Klonisky DJ. Autophagy participates in, well, just about everything. Cell Death Differ. 2020;27(3):813–21.
24. Yang Y, Klonisky DJ. Autophagy and disease: unanswered questions. Cell Death Differ. 2020;27(3):858–71.
25. Vance JE. Inter-organelle membrane contact sites: implications for lipid metabolism. Biol Direct. 2020;15(1):24.
26. Duggal NA, Niemiro G, Harridge SDR, Simpson RJ, Lord JM. Can physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity? Nat Rev Immunol. 2019;19(9):563–72.
27. Tidball JG. Regulation of muscle growth and regeneration by the immune system. Nat Rev Immunol. 2017;17(3):165–78.
28. Yang W, Hu P. Hierarchical signaling transduction of the immune and muscle cell crosstalk in muscle regeneration. Cell Immunol. 2018;326:2–7.
29. Farup J, Madero L, Puri PL, Mikkelsen UR. Interactions between muscle stem cells, mesenchymal-derived cells and immune cells in muscle homeostasis, regeneration and disease. Cell Death Dis. 2015;6:e1830.
31. Almada AE, Wagers AJ. Molecular circuitry of stem cell fate in skeletal muscle regeneration, ageing and disease. Nat Rev Mol Cell Biol. 2016;17(5):267–79.

32. Chazaud B. Inflammation and skeletal muscle regeneration: leave it to the macrophages! Trends Immunol. 2020;41(6):481–92.

33. Sassa FA, Fuchs M, Pumberger M, Geissler S, Duda GN, Perka C, Schmidt-Bleek K. Immunology guides skeletal muscle regeneration. Int J Mol Sci. 2018;19(3):66.

34. Frenette J, Cai B, Tidball JG. Complement activation promotes muscle inflammation during modified muscle use. Am J Pathol. 2000;156(6):2103–10.

35. Collins RA, Grounds MD. The role of tumor necrosis factor-alpha (TNF-alpha) in skeletal muscle regeneration. studies in TNF-alpha(+/-) and TNF-alpha(-/-)/LT-alpha(-/-) mice. J Histochem Cytochem. 2001;49(8):989–1001.

36. Radley HG, Grounds MD. Cromolyn administration (to block mast cell degranulation) reduces necrosis of dystrophic muscle in mdx mice. Neurobiol Dis. 2006;23(2):387–97.

37. Supigamo MA, Vago JP, Perretti M, Teixeira MM. Mediators of the resolution of the inflammatory response. Trends Immunol. 2019;40(3):212–27.

38. Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol. 2010;298(5):R173–1187.

39. Yang W, H Philipp. Skeletal muscle regeneration is modulated by inflammation. J Orthop Translat. 2018;13:25–32.

40. Sciorati C, Rigamonti E, Manfredi AA, Rovere-Querini P. Cell death, immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol. 2010;299(3):R832-842.

41. Heredia JE, Mukundan L, Chen FM, Mueller AA, Deo RC, Locksley RM, Rando TA, Chawla A. Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. Cell. 2013;153(2):376–88.

42. Martinez CO, McHale MJ, Wells JT, Ochoa Q, Michalek JE, McManus LM, Shireman PK. Regulation of skeletal muscle regeneration by CCR2-activating chemokines is directly related to macrophage recruitment. Am J Physiol Regul Integr Comp Physiol. 2010;299(3):R832-842.

43. Contreras-Shannon V, Ochoa O, Reyes-Reyna SM, Sun D, Michalek JE, Kuziel WA, McManus LM, Shireman PK. Fat accumulation with altered inflammation and regeneration in skeletal muscle of CCR2(-/-) mice following ischemic injury. Am J Physiol Cell Physiol. 2007;292(2):C593-967.

44. Shireman PK, Contreras-Shannon V, Ochoa O, Karra BP, Michalek JE, McManus LM. MCP-1 deficiency causes altered inflammation with impaired skeletal muscle regeneration. J Leukoc Biol. 2007;81(3):775–85.

45. Warren GL, Hulderman T, Mishra D, Gao X, Millecchia L, O’Farrell L, Kuziel WA, Simeonova PP. Chemokine receptor CCR2 involvement in skeletal muscle regeneration. Trends Immunol. 2019;41(7):418–27.

46. Arnold L, Henry A, Poron F, Baba-Amer Y, van Rooijen N, Plonquet A, Cheng M, Nguyen MH, Fantuzzi G, Koh TJ. Endogenous interferon-gamma-induced differentiation and downstream activation signals of the interferon-like growth factor receptor in myoblasts. J Immunol. 2004;172(12):7713–20.

47. Langen RC, Van Der Velden JL, Schols AM, Kelders MC, Wouters EF, Janssen-Heininger YM. Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization. FASEB J. 2004;18(2):227–37.

48. Saclier M, Cuveiller S, Magnan M, Mounier R, Chazaud B. Monocyte/macrophage interactions with myogenic precursor cells during skeletal muscle regeneration. FEMS J. 2013;280(17):4118–30.

49. Lemos DR, Babaeijandaghi F, Low M, Chang CK, Lee ST, Fiore D, Zhang RH, Natarajan A, Nedosposav SA, Rossi FM. Nilotinib reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors. Nat Med. 2015;21(7):786–94.

50. Ratnayake D, Nguyen PD, Rossello FJ, Wimmer VC, Tan JL, Galvis LA, Julier Z, Wood AJ, Boudier T, Isakai AI, et al. Macrophages provide a transient muscle stem cell niche via NAMPT secretion. Nature. 2021;591(7849):281–7.

51. Xu F, Xiao J, Wei Y, Li S, Liu Y, Yin J, Sun K, Sun H, Wang H, Zhang Z, et al. Combination of inflammation-related cytokines promotes long-term muscle stem cell expansion. Cell Res. 2015;25(6):655–73.

52. Quarta M, Rando TA. Mimicking the niche. cytokines expand muscle stem cells. Cell Res. 2015;25(7):761–2.

53. Varga T, Mounier R, Patsalos A, Gogolak P, Peloquin M, Horvath A, Pap A, Daniel B, Nagy G, Pintye E, et al. Macrophage PPARgamma, a lipid activated transcription factor controls the growth factor GDF3 and skeletal muscle regeneration. Immunity. 2016;45(5):1038–51.

54. Latroche C, Weiss-Gayet M, Muller L, Giaitsa C, Leblanc P, Liout S, Lenarz S, Abou-Khalil R, Verger N, Bardot P, et al. Coupling between myogenin and angiogenesis during skeletal muscle regeneration is stimulated by restorative macrophages. Stem Cell Rep. 2017;9(6):2018–33.

55. Diskin C, Ryan TJ, O’Neill LAJ. Modification of proteins by metabolites in immunity. Immunity. 2021;54(1):19–31.

56. Muri J, Kopf M. Redox regulation of immunometabolism. Nat Rev Immunol. 2021;21(6):363–81.

57. Giannakis N, Sansbury BE, Patsalos A, Hays TT, Riley CO, Han X, Spite M, Nagy L. Dynamic changes to lipid mediators support transitions among macrophage subtypes during muscle regeneration. Nat Immunol. 2019;20(5):626–36.

58. Mounier R, Theret M, Arnold L, Cuveiller S, Bultot L, Goransson O, Sanz N, Ferry A, Sakamoto K, Forez M, et al. AMF/Calpha1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration. Cell Metab. 2013;18(2):251–64.

59. Tonkin J, Temmerson L, Sampson RD, Gallego-Colon E, Barberi L, Bilbao D, Schneider MD, Musaro A, Rosenthal N. Monocyte/macrophage-derived IGF-1 orchestrates murine skeletal muscle regeneration and modulates autocrine polarization. Mol Ther. 2015;23(7):1189–200.

60. Tidball JG, Welc SS. Macrophage-derived IGF-1 is a potent coordinator of myogenesis and inflammation in regenerating muscle. Mol Ther. 2015;23(7):1134–5.

61. Wei J, Gronert K. Eicosanoid and specialized proresolving mediator regulation of lymphoid cells. Trends Biochem Sci. 2019;44(3):124–5.

62. Peebles RS Jr. Prostaglandins in asthma and allergic diseases. Pharmacol Ther. 2019;193:1–19.

63. Norel X, Supigamo Y, Ozen G, Abdelazeeem H, Amgoud Y, Bouladoun A, Bassiouni W, Goepp M, Mani S, Manikpurage HD, et al. International union of basic and clinical pharmacology: CIX. Differences and similarities between human and rodent prostaglandin E2 receptors (EP1-4) and prostacyclin receptor (IP): specific roles in pathophysiologic conditions. Pharmacol Rev. 2020;72(4):910–68.

64. Ho ATV, Palla AR, Blake MR, Yucel ND, Wang YX, Magnussen KEG, Holbrook CA, Kraft PE, Delp SL, Blau HM. Prostaglandin E2 is essential for efficacious skeletal muscle stem-cell function, augmenting regeneration and strength. Proc Natl Acad Sci USA. 2017;114(26):6675–84.

65. Panduro M, Benoist C, Mathis D. Tissue tregs. Annu Rev Immunol. 2016;34:609–33.
84. Kuswanto W, Burzyn D, Panduro M, Wang KK, Jang YC, Wagers AJ, Benoist C, Mathis D. Poor repair of skeletal muscle in aging mice reflects a defect in local, interleukin-33-dependent accumulation of regulatory T cells. Immunity. 2016;44(2):355–67.

85. Burzyn D, Kuswanto W, Kolodin D, Shadchon J, Cerletti M, Jang Y, Sefik E, Tan TG, Wagers AJ, Benoist C, et al. A special population of regulatory T cells potentiates muscle repair. Cell. 2013;155(6):1282–95.

86. Villalta SA, Rosenthal W, Martinez L, Kaur A, Sparwasser T, Tidball JG, Margeta M, Spencer MJ, Bluestone JA. Regulatory T cells suppress muscle inflammation and injury in muscular dystrophy. Sci Transl Med. 2014;6(258):258ra142.

87. Afzali AM, Muntefering T, Wiendl H, Meuth SG. T cell dysregulation in neuromuscular disease. Nat Rev Neurol. 2011;7(12):685–92.

88. Zhou S, Zhang W, Cai G, Ding Y, Wei C, Li S, Yang Y, Qin J, Liu D, Fang J, Zhang S, Liu Z, Pan Y, Cao L, Hou P, Chen Y, Zhang Y, Li X, Liu R, et al. Skeletal muscle cells actively shape (auto)immune responses. Autoimmun Rev. 2018;17(5):518–29.

89. Shu L, Niu C, Li R, Huang T, Wang Y, Huang M, Ji N, Zheng Y, Chen X, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11(1):361.

90. Chen J, Lu H, Melino G, Boccià S, Piacentini M, Ricciardi W, Wang Y, Shi Y, Zhu T. COVID-19 infection: the China and Italy perspectives. Cell Death Dis. 2020;11(6):438.

91. Agrati C, Sacchi A, Bordoni V, Cimini E, Notari S, Grassi G, Casetti R, Tartaglia E, Lalle L, D'Agambra A, et al. Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19). Cell Death Differ. 2020;27(11):1396–207.

92. Noce A, Santoro ML, Mannoni G, D'Agostini C, Amelio I, Duggento A, Tesauro M, Di Danièle N. Serological determinants of COVID-19. Biol Direct. 2020;15(1):21.

93. Ehsani S. COVID-19 and iron dysregulation: distant sequence similarity between hepcidin and the novel coronavirus spike glycoprotein. Biol Direct. 2020;15(1):19.

94. Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X,ucci E, Piacentini M, Ippolito G, Melino G. COVID-19 infection: the perspectives on immune responses. Cell Death Differ. 2020;27(5):1451–4.

95. Sharma A, Kumar Sharma S, Shi Y,ucci E, Carafoli E, Melino G, Battacherjee A, Das G. BCG vaccination policy and preventive chloroquine usage: Do they have an impact on COVID-19 pandemic? Cell Death Dis. 2020;11(7):516.

96. Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P, Zheng H, Sundaram B, Banoth B, Maliredi RKS, et al. Synergism of TNFα and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell. 2021;184(1):149e117–168e117.

97. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, Shan G, Meng F, Du D, Wang S, et al. Transplantation of A2E(−) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis. 2020;11(2):216–28.

98. Shu L, Niu C, Li R, Huang T, Wang Y, Huang M, Ji N, Zheng Y, Chen X, Shi L, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11(1):361.

99. Peng X, Xu R, Wang S, Xu Z, Zhang C, Li Y, Yang T, Shi L, Fu J, Jiang T, et al. Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther. 2020;5(1):172.

100. Feng Y, Huang J, Wu J, Xu Y, Chen B, Jiang L, Xiang H, Peng Z, Wang X. Safety and feasibility of umbilical cord mesenchymal stem cells in patients with COVID-19 pneumonia: a pilot study. Cell Prolif. 2020;53(12):12947.

101. Shi L, Huang H, Lu X, Yan X, Jiang X, Xu R, Wang S, Zhang C, Yuan X, Xu Z, et al. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial. Signal Transduct Target Ther. 2021;6(1):58.

102. Sanchez-Guijo F, Garcia-Arranz M, Lopez-Parras M, Monedero P, Mata-Martinez C, Santos A, Sagredo V, Alvarez-Avello JM, Guerrero JE, Perez-Calvo C, et al. Adipose-derived mesenchymal stromal cells for the treatment of patients with severe SARS-CoV-2 pneumonia requiring mechanical ventilation: A proof of concept study. EJClinicalMedicine. 2020;25:100454.